What is the recommended dosing schedule for the Cervarix (bivalent human papillomavirus) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cervarix Dosing Schedule

Cervarix (bivalent HPV vaccine) is administered as a 3-dose series at 0,1, and 6 months for females aged 9-25 years, with each dose being 0.5 mL given intramuscularly.

Standard Dosing Regimen

The licensed dosing schedule for Cervarix consists of:

  • Dose 1: Month 0 (initial dose)
  • Dose 2: Month 1 (1 month after first dose)
  • Dose 3: Month 6 (6 months after first dose)

Each dose is 0.5 mL administered intramuscularly, preferably in the deltoid muscle 1, 2, 3.

Age-Based Recommendations

Routine Vaccination

  • Primary target: Females aged 11-12 years
  • Can initiate as early as: Age 9 years
  • Catch-up vaccination: Females aged 13-25 years who have not been previously vaccinated or have not completed the series 1, 2

Immunogenicity by Age

The vaccine demonstrates highest immunogenicity in younger age groups. Girls aged 9-14 years achieve antibody titers approximately twice as high as those in women aged 15-25 years, and responses in women aged 26-55 years remain at least 8-fold higher than natural infection levels 3.

Alternative Dosing Considerations

Two-Dose Schedule (Emerging Evidence)

Recent research suggests that two doses administered at 0 and 6 months may provide comparable protection to the standard 3-dose schedule in girls aged 9-14 years:

  • Vaccine efficacy for 2 doses: 84.1% (95% CI: 50.2%-96.3%) 4
  • Vaccine efficacy for 3 doses: 80.9% (95% CI: 71.1%-87.7%) 4
  • Non-inferiority was maintained at 24 months for the 2-dose schedule at 0 and 6 months in girls aged 9-14 years compared to the 3-dose schedule in women aged 15-25 years 1

However, the 2-dose schedule is NOT currently part of the FDA-approved labeling for Cervarix. The licensed indication remains the 3-dose series.

Minimum Dosing Intervals

If the standard schedule is interrupted:

  • Minimum interval between doses 1 and 2: 4 weeks
  • Minimum interval between doses 2 and 3: 12 weeks (approximately 3 months)
  • The series does not need to be restarted if interrupted; simply continue with the next dose 1

Important Clinical Considerations

Pre-Vaccination Screening

  • No HPV testing required before vaccination (no Pap test, HPV DNA test, or antibody testing needed)
  • Vaccination is recommended even for sexually active females who may have been exposed to HPV 2

Concurrent Administration

  • Cervarix can be administered simultaneously with other age-appropriate vaccines (e.g., Tdap, meningococcal vaccine)
  • Use separate syringes and different anatomic sites 2

Continued Screening

  • Cervical cancer screening must continue after vaccination, as Cervarix protects against only HPV types 16 and 18 (responsible for approximately 70% of cervical cancers)
  • Vaccination does not eliminate the need for routine Pap testing 2, 3

Common Pitfalls to Avoid

  1. Do not delay vaccination waiting for "ideal" timing—earlier vaccination (ages 9-14) provides superior immunogenicity
  2. Do not perform pre-vaccination HPV testing—it is unnecessary and delays protection
  3. Do not withhold vaccination from sexually active females—they still benefit from protection against HPV types they haven't encountered
  4. Do not discontinue cervical cancer screening in vaccinated women

Contraindications

  • History of immediate hypersensitivity to yeast or any vaccine component
  • Pregnancy (defer subsequent doses until after pregnancy completion; registry available at 1-800-986-8999) 5

References

Related Questions

In a 31-year-old woman who completed the three-dose human papillomavirus (HPV) vaccine series at ages 16 and 17, is there any indication for a fourth HPV vaccine dose?
What is the recommended dose of Cervarix (human papillomavirus vaccine)
How many HPV vaccine doses does a 16-year-old female need if she has already received two doses?
What is the recommended HPV vaccine dosing schedule for different age groups?
What are the recommended HPV vaccination guidelines, including age, dosing schedule, and contraindications, for pre‑teen females?
What is the maximum recommended dose of dexamethasone for an adult patient?
Does gabapentin cause or worsen delirium?
What is the appropriate management for a patient with ambulatory blood pressure monitoring showing average 24‑hour 132/77 mmHg, daytime 133/80 mmHg, nighttime 129/69 mmHg, and a non‑dipper nocturnal pattern?
If a penile culture grows Bacteroides, is amoxicillin‑clavulanate (Augmentin) sufficient for treatment?
Can cold agglutinin autoimmune hemolytic anemia cause blood samples collected in an EDTA tube to clot, and how can this be prevented?
What is the appropriate treatment for facial pityriasis alba?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.